Zuvog 0.2 Tab

Tablet

Management of type 2 diabetes mellitus; helps control post-meal (postprandial) blood glucose levels, usually as an add-on to diet/exercise and/or other antidiabetic medicines.

Voglibose is an alpha-glucosidase inhibitor that delays the breakdown and absorption of carbohydrates in the small intestine. This reduces the rise in blood sugar after meals and helps improve overall glycaemic control.

Oral tablet. Typically taken just before meals (or with the first bite of food) as prescribed by a doctor. Swallow with water; follow diet and exercise advice and monitor blood glucose regularly.

Flatulence, abdominal pain, diarrhoea, nausea, bloating, constipation, increased liver enzymes, hypoglycaemia (when used with other antidiabetics)

Use under medical supervision in diabetes. Not recommended in type 1 diabetes or diabetic ketoacidosis. Use with caution in intestinal disorders (inflammatory bowel disease, colonic ulceration), intestinal obstruction/predisposition, or significant digestive disorders. Monitor liver function if advised; stop and seek care if severe abdominal symptoms occur. Hypoglycaemia risk increases when combined with insulin/sulfonylureas—carry glucose and treat lows with glucose (not sucrose).

Insulin, sulfonylureas and other antidiabetics (increased hypoglycaemia risk), intestinal adsorbents (may reduce effect), digestive enzyme preparations (may reduce effect), laxatives (may alter GI effects), alcohol (may increase hypoglycaemia risk when on other antidiabetics)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Voglibose 0.2 mg tablet (generic), Vobit 0.2 Tablet, Vogli 0.2 Tablet, Volibo 0.2 Tablet, Vocarb 0.2 Tablet